Jump to content


From Wikipedia, the free encyclopedia
Clinical data
ATC code
  • None
  • α-phenyl-1-(2-phenylethyl)-4-piperidine methanol
CAS Number
PubChem CID
CompTox Dashboard (EPA)
Chemical and physical data
Molar mass295.426 g·mol−1
3D model (JSmol)
  • OC(c1ccccc1)C3CCN(CCc2ccccc2)CC3
  • InChI=1S/C20H25NO/c22-20(18-9-5-2-6-10-18)19-12-15-21(16-13-19)14-11-17-7-3-1-4-8-17/h1-10,19-20,22H,11-16H2

Glemanserin (INN) (developmental code name MDL-11,939) is a drug which acts as a potent and selective 5-HT2A receptor antagonist.[1] The first truly selective 5-HT2A ligand to be discovered, glemanserin resulted in the development of the widely used and even more potent and selective 5-HT2A receptor antagonist volinanserin (MDL-100,907), which is a fluorinated analogue.[2] Though it was largely superseded in scientific research by volinanserin, glemanserin was investigated clinically for the treatment of generalized anxiety disorder.[3] However, it was ultimately found to be ineffective and was not marketed.[3]

See also[edit]


  1. ^ Dudley MW, Wiech NL, Miller FP, Carr AA, Cheng HC, Roebel LE, et al. (1988). "Pharmacological effects of MDL 11,939: A selective, centrally acting antagonist of 5-HT2 receptors". Drug Development Research. 13 (1): 29–43. doi:10.1002/ddr.430130104. S2CID 85075328.
  2. ^ van Wijngaarden I, Soudijn W (10 July 1997). "5-HT2A, 5-HT2B, and 5-HT2C Receptor Ligands". In Olivier B (ed.). Serotonin Receptors and Their Ligands. Elsevier. p. 167. ISBN 978-0-444-82041-9. Retrieved 6 May 2012.
  3. ^ a b Sramek JJ, Robinson RE, Suri A, Cutler NR (February 1995). "Efficacy trial of the 5-HT2 antagonist MDL 11,939 in patients with generalized anxiety disorder". Journal of Clinical Psychopharmacology. 15 (1): 20–22. doi:10.1097/00004714-199502000-00004. PMID 7714223.